Central Nervous System 209

32.19 The following opioid is more potent than morphine:

A. Pethidine
B. Fentanyl
C. Dextropropoxyphene
D. Tramadol (p. 425)
32.20 Indicate the opioid analgesic that is used as
transdermal patch for chronic and cancer pain:
A. Morphine
B. Pentazocine
C. Fentanyl
D. Tramadol (p. 425, 427)
32.21 The distinctive feature(s) of methadone compared to
morphine is/are:
A. High oral bioavailability
B. High plasma protein and tissue binding
C. Delayed and milder withdrawal symptoms in
dependent subjects
D. All of the above (p. 425-426)
32.22 The following opioid analgesic is similar to codeine in
pharmacological profile but is less constipating:
A. Methadone
B. Buprenorphine
C. Butorphanol
D. Dextropropoxyphene (p. 426)
32.23 Select the analgesic which acts through opioid as well
as additional spinal monoaminergic mechanisms:
A. Tramadol
B. Ethoheptazine
C. Dextropropoxyphene
D. Alfentanil (p. 426)

32.19 B 32.20 C 32.21D 32.22D 32.23 A

210 MCQs in Pharmacology

32.24 An opioid analgesic is preferred over aspirin like

analgesic in the following condition:
A. Acute gout
B. Burn
C. Toothache
D. Neuralgia (p. 427)
32.25 Morphine affords symptomatic relief of dyspnoea in
acute left ventricular failure by the following
mechanisms except:
A. Bronchodilatation
B. Depression of respiratory centre
C. Reduction in cardiac preload
D. Shift of blood from pulmonary to systemic
circuit (p. 427)
32.26 Morphine has high affinity for the following opioid
receptor(s):
A. μ (Mu)
B. κ (Kappa)
C. δ (Delta)
D. All of the above (p. 428)
32.27 Features of µ (Mu) opioid receptor include the
following except:
A. Acts by inhibiting cAMP formation
B. Mediates miotic action
C. Mediates low ceiling respiratory depression
D. Mediates high ceiling supraspinal analgesia
(p. 428, 429)
32.28 Nalorphine is nearly equipotent analgesic as morphine,
but is not used clinically as an analgesic because:
A. It causes more marked respiratory depres-
sion
B. It has higher abuse potential
C. It antagonises the action of morphine
D. It produces prominent dysphoric effects
(p. 430)
32.24 B 32.25 A 32.26 A 32.27 C 32.28D
 Central Nervous System 211

32.29 Which of the following is an agonist-antagonist type

of opioid analgesic:
A. Pethidine
B. Pentazocine
C. Fentanyl
D. Buprenorphine (p. 430, 431)
32.30 Select the opioid analgesic which acts primarily
through κ (kappa) opioid receptor:
A. Pentazocine
B. Methadone
C. Buprenorphine
D. Pethidine (p. 431)
32.31 The following opioids are κ (kappa) receptor analgesics
except:
A. Buprenorphine
B. Butorphanol
C. Nalbuphine
D. Pentazocine (p. 429, 431, 432)
32.32 Choose the correct statement about pentazocine:
A. It causes bradycardia and fall in blood
pressure
B. Its subjective effects are pleasurable at low
doses but turn unpleasant at high doses
C. It induces vomiting frequently
D. It substitutes for morphine in dependent
subjects (p. 431)
32.33 Pentazocine differs from morphine in that:
A. It is inactive by the oral route
B. It does not produce physical dependence
C. It has a lower ceiling of analgesic effect
D. Its action is not blocked by naloxone
(p. 431)
32.29 B 32.30 A 32.31 A 32.32 B 32.33 C
212 MCQs in Pharmacology

32.34 The following is true of buprenorphine:

A. It is an agonist-antagonist type of opioid
analgesic
B. Its subjective effects are different from those
of morphine
C. Naloxone is largely ineffective in reversing
its effects
D. It produces mydriasis (p. 432)
32.35 The following are pure opioid antagonists except:
A. Nalmfene
B. Nalbuphine
C. Naloxone
D. Naltrexone (p. 431, 432, 433)
32.36 Select the correct statement about Naloxone:
A. It equally blocks μ, κ and δ opioid receptors
B. It blocks μ receptors at lower doses than
those needed for others
C. It blocks κ receptors at lower doses than
those needed for others
D. It blocks δ receptors at lower doses than
those needed for others (p. 432)
32.37 Which action of morphine is incompletely reversed by
naloxone:
A. Analgesia
B. Respiratory depression
C. Sedation
D. Miosis (p. 432)
32.38 Lower dose of naloxone is required to:
A. Antagonise the actions of nalorphine
B. Antagonise the actions of pentazocine
C. Precipitate withdrawal in mildly morphine
dependent subjects
D. Precipitate withdrawal in highly morphine
dependent subjects (p. 423. 433)
32.34 C 32.35 B 32.36 B 32.37 C 32.38D
 Central Nervous System 213

32.39 Select the opioid antagonist that is preferred for long

term opioid blockade therapy of post addicts:
A. Nalorphine
B. Naloxone
C. Naltrexone
D. Nalbuphine (p. 433)
32.40 The following is not true of naltrexone:
A. It produces agonistic actions of its own in the
absence of morphine
B. It is active orally
C. It has a long duration of action
D. It can reduce craving for alcohol in chronic
alcoholics (p. 433)
32.41 The following statement is true about endogenous
opioid peptides:
A. They activate only μ opioid recepors
B. They do not occur in peripheral tissues
C. They mediate stress induced analgesia
D. Naloxone fails to antagonise their action
(p. 439)
33.1 Strychnine produces convulsions by:
A. Stimulating NMDA receptors
B. Facilitating the excitatory transmitter gluta-
mate
C. Blocking the inhibitory transmitter GABA
D. Blocking the inhibitory transmitter glycine
(p. 435)
33.2 The following drug has been used to stimulate respi-
ratory and vasomotor centres as an expedient mea-
sure, because it has the least propensity to induce
convulsions:
A. Pentylenetetrazole
B. Doxapram
C. Bicuculline
D. Amphetamine (p. 436)
32.39 C 32.40 A 32.41 C 33.1D 33.2 B